Boundless Bio, Inc.
BOLDAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2025 |
| Leerink Partners | downgrade | Outperform →Market Perform | May 28, 2025 |
| Guggenheim | downgrade | Buy →Neutral | Dec 13, 2024 |
| Evercore ISI Group | downgrade | Outperform →In Line | Dec 8, 2019 |
| JP Morgan | downgrade | Overweight →Neutral | Dec 5, 2019 |
| SVB Leerink | downgrade | Outperform →Perform | Dec 4, 2019 |
| BMO Capital | downgrade | Outperform →Perform | Dec 3, 2019 |
| SVB Leerink | downgrade | Outperform →Market Perform | Dec 3, 2019 |
| Raymond James | downgrade | Outperform →Perform | Dec 3, 2019 |
| Chardan Capital | downgrade | Buy →Neutral | Dec 3, 2019 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Dec 2, 2019 |
| Wedbush | downgrade | Outperform →Neutral | Dec 2, 2019 |
| Raymond James | downgrade | Outperform →Market Perform | Dec 2, 2019 |
| Piper Jaffray | downgrade | Overweight →Neutral | Dec 2, 2019 |
| Baird | upgrade | Underperform →Neutral | Dec 2, 2019 |
| Citigroup | upgrade | Sell →Neutral | Dec 2, 2019 |
| BMO Capital | downgrade | Outperform →Market Perform | Dec 2, 2019 |
| Guggenheim | downgrade | Buy →Neutral | Dec 2, 2019 |
| Evercore ISI Group | upgrade | In Line →Outperform | Nov 18, 2019 |
| Baird | maintain | Underperform | Oct 3, 2019 |
| Chardan Capital | maintain | Buy | Sep 2, 2019 |
| SVB Leerink | maintain | Outperform | Apr 16, 2019 |
| Chardan Capital | upgrade | Neutral →Buy | Feb 24, 2019 |
| Guggenheim | upgrade | Neutral →Buy | Jan 10, 2019 |
| Citigroup | maintain | Neutral | Dec 9, 2018 |
Earnings History
Next report: Apr 1, 2027 · EPS est. $-0.32| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 4, 2026 | $-1.06 | $-1.06 | — | — |
| May 8, 2026 | $-0.60 | $-0.51 | — | — |
| Mar 9, 2026 | $-0.58 | $-0.44 | — | — |
| Nov 5, 2025 | $-0.62 | $-0.53 | — | — |
| Aug 5, 2025 | $-0.70 | $-0.75 | — | — |
| May 9, 2025 | $-0.71 | $-0.68 | — | — |
| Mar 27, 2025 | $-0.74 | $-0.74 | — | — |
| Nov 7, 2024 | $-0.74 | $-0.76 | — | — |
News
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial bene
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
- Daphne Karydas appointed as President and Chief Financial Officer - Weston Miller, MD, appointed as Chief Medical Officer - Additional appointments: Nina Hunter, PhD, as Chief Development Officer and Shiva G. Fritsch as Chief Corporate Affairs Officer - Lead program SERP-01 on track for Phase 2/3 initiation in late 2026 or early 2027 NEW YORK, Sept.
Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer Piers Ingram, PhD, Co-Founder, transitions to Senior Advisor and continues to serve on the Board of Directors; Jerome Boyd-Kirkup, PhD, founding Chief Scientific Officer, transitions to Senior Scientific Advisor SAN DIEGO and SEATTLE and SINGAPORE, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics (“Callio” or “the Company”), a clinical-stage …